Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. - Wikidata - awgldk - TriplyDB

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

http://www.wikidata.org/entity/Q33586491

about

EZH2 in normal hematopoiesis and hematological malignancies c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune Role of MYC in B Cell Lymphomagenesis.The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex EZH2: biology, disease, and structure-based drug discovery Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells Polycomb genes, miRNA, and their deregulation in B-cell malignancies 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.Divergence of transcriptional landscape occurs early in B cell activation.Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma Emerging role of transcription factor-microRNA-target gene feed-forward loops in cancer.Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell.Small molecules targeting microRNA for cancer therapy: Promises and obstacles.MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.Targeting RNA polymerase I to treat MYC-driven cancer.Targeted therapy of acute myeloid leukemia.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.Cutting Edge: EZH2 Promotes Osteoclastogenesis by Epigenetic Silencing of the Negative Regulator IRF8.Targeting epigenetics for cancer prevention by dietary cancer preventive compounds--the case of miRNA.Epigenomics and targeted therapy in cancer.Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.

P2860

Q26779821-968FAA89-2DDD-48E1-8879-8E49E375A299 Q26851373-B6E498EE-B06F-4096-BABF-B85A303B7242 Q27013740-E2253F4A-99E5-4C58-B667-4C142A72014F Q33608499-04661582-F8D3-49B7-AA2D-FC2399DFB5DB Q33838260-5EABDD65-A46C-42F3-B575-65D84B447384 Q33853887-631AF314-E02C-403C-8F66-E499A8FC1E1A Q34016520-16757828-2732-4440-94B9-92A379ADB7D7 Q34393753-45269806-0903-4FBC-956A-1D544E972F86 Q34860750-140F2331-9AB0-4396-8968-54F023D67EE0 Q35002896-F49BBD61-3725-4AC3-9B08-2355F7A0B06F Q35103527-62FB4F77-A3A3-4CCD-B5A5-2F83594C15EC Q35172602-9BA4A722-026A-4B62-8456-6F7BD4D0A915 Q35615412-F8908701-EE96-4B9A-AFC0-36C2229A74A5 Q35740455-1CB237F1-0087-412B-A633-FDE8C6F6892F Q35949238-D5982B7C-F68C-4FDB-BA95-1D582DDA9C3A Q36140942-D05A13B8-399C-4EA2-8F8B-3A5537829911 Q36185272-245497C3-4499-45DB-838E-2F3DEE211273 Q36567511-5BD370C7-08FB-4FC5-87F5-593354231805 Q36815139-20969750-2C46-48F2-AE4A-7C13F85EA916 Q37207661-E88AC095-914C-4105-A5B1-5F63A1E60C48 Q37295285-82412B38-E0FD-40B9-9066-7C061680883F Q37558207-46FAD3AA-5132-445F-AA8D-939ED6AB9D7F Q37705811-6283FDC0-439F-4815-BB37-228EFA29D42D Q38194418-4725862F-8877-478B-B497-D85F05605D90 Q38333251-41F198F2-AAE8-4E5B-BEF0-6F174705229B Q38476564-8AC1008B-4A27-4DAC-820A-3386F1E65B81 Q38542092-0A8D0825-455E-4ED9-BB2A-33B78AE9F522 Q38594002-54ECA52D-E79B-47D6-BAC4-822E74C13446 Q38664822-DCAD7E6E-605F-49FB-9B6F-055A4362B4DF Q38913027-36457A0D-BCF0-4234-9B19-62AB5E8C6C40 Q39379624-9C513F8F-CC12-4C21-8E08-E2A04A2FBE06 Q41858539-496BFDB4-CD5C-4A3A-850C-59C30693AA55 Q41955169-FF902D96-B9F8-4B0D-AD61-626CC82F533C Q46117582-304DF469-3A76-4BD5-B2F1-B8A5FFB1BCD2 Q49036164-DFCC08A3-5126-4D0D-A8AE-D681718DAB0E Q51347784-C5A88DAF-5BAF-4D60-86D4-72A4BD2F8032 Q51747268-1D7A7543-8FE1-4CF2-A315-E72BF662597E Q55018505-CCB57F6C-9B56-49AE-8C90-08EB59B2D2E6 Q55664994-5BD0ECD6-167B-4009-B30D-022EA17F60B4

P2860

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

http://www.wikidata.org/entity/Q33586491

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@ast

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@en

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@nl

type

label

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@ast

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@en

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@nl

prefLabel

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@ast

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@en

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@nl

P1433

Q33586491-5B6A62CA-C607-4175-834F-BD67D5DF108A

P1476

Q33586491-C0140255-0B38-4DFD-B0CA-EAE3F12EA5E5

P2093

Q33586491-22583AE1-62B1-4C50-96CE-9D6F5BA829C4

Q33586491-463DCFA8-4813-42AB-9A48-4C75ED826645

Q33586491-4E5C660F-06B2-4102-B888-84F85544007B

Q33586491-713EC297-AA5F-4D01-8142-E8F1631E714F

Q33586491-7C44A16B-FF24-4ABE-80D8-F427244667A5

Q33586491-80513F31-9C1F-4BC2-8AEF-29901C1ECFCA

Q33586491-A2195E1E-BE0B-49D3-BC4C-72E42CA39817

Q33586491-ACFF7005-A0D6-4604-A6EC-BDCD689D4BFB

Q33586491-C3C234CB-1862-49AD-B449-B36FDDB8F640

Q33586491-CE6BF7CE-FE96-4FCE-922E-C287765A40E3

P2860

Q33586491-12C86AE6-8171-42D9-9098-F8C2A5F4B77F

Q33586491-1B2F1BD2-6F1B-4CAC-A279-918D652AABAB

Q33586491-27ED60DA-D6E4-418E-AAE3-4DAB57616E99

Q33586491-329AAB9E-084F-4C8C-AAAB-7C778D761887

Q33586491-34D8DC1F-1BA0-407C-B10C-630305AE7D10

Q33586491-41F1F471-DD43-48CA-ABC7-D6DCF64B6C8F

Q33586491-459E8E66-FBCF-4534-8D24-2F2BEA555A91

Q33586491-4A3EBF16-4594-4F96-B808-78AFF0BC9858

Q33586491-4B50004D-7E1E-4F8E-976C-882ED84B5A06

Q33586491-4BA4CCA2-17D5-4BAD-A63C-B0000BB8897D

P2888

Q33586491-A911824F-BE98-454E-BCDC-28B713A64037

P304

Q33586491-DE68FE7D-9564-4A33-B16B-E82F49C5736C

P31

Q33586491-4CC1DC85-2211-4106-BC90-A7BAC49C4B3F

P356

Q33586491-384FE8D8-F7D1-4605-9FBB-B2FADE3C1EF1

P433

Q33586491-BD5A4763-EBAD-4718-9D77-999D3EDAF5D2

P478

Q33586491-3CB849DD-47EE-4FEF-A776-0EAE574A45CD

P577

Q33586491-3377EA4A-C3D2-4678-BFBD-1391B9126DC2

P5875

Q33586491-434273D4-3E4D-410D-BB4F-A0D76F486DFA

P6179

Q33586491-E18B3100-8B8D-4216-86D0-14E7DC0D6839

P698

Q33586491-C7DD01DD-C0E7-47EB-AF30-4B4D17FF17FA

P932

Q33586491-7B0EA749-7A08-419D-9B34-D4C5CDECA8B6

P356

P1433

P1476

Disruption of the MYC-miRNA-EZ ...... ma survival and clonogenicity.

@en

P2093

A Huang

http://www.w3.org/2001/XMLSchema#string

E Sotomayor

http://www.w3.org/2001/XMLSchema#string

J Tao

http://www.w3.org/2001/XMLSchema#string

J Wang

http://www.w3.org/2001/XMLSchema#string

S Chen-Kiang

http://www.w3.org/2001/XMLSchema#string

T Lwin

http://www.w3.org/2001/XMLSchema#string

V E Marquez

http://www.w3.org/2001/XMLSchema#string

W S Dalton

http://www.w3.org/2001/XMLSchema#string

X Zhang

http://www.w3.org/2001/XMLSchema#string

X Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Widespread microRNA repression by Myc contributes to tumorigenesis

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

A microRNA polycistron as a potential human oncogene

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2

P2888

P304

2341-2350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.94

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236090183

http://www.w3.org/2001/XMLSchema#string

P6179

1009181905

http://www.w3.org/2001/XMLSchema#string

P698

23538750

http://www.w3.org/2001/XMLSchema#string

P932

4015113

http://www.w3.org/2001/XMLSchema#string